Katie McConnell

Acting for HTC its long-running dispute against IPCom, including ontianing a declaration of non-infringement for a workaround to an SEP, and striking out IPCom's claim for damages for non-UK devices.

Acting for Merck Sharp and Dohme in first UK case dealing with the interpretation of European legislation regarding the Specific Mechanism for parallel imports.

Representing Vodafone in litigation against IPCom concerning the infringement and validity of alleged SEPs, including successfully invoking both a workaround and the rarely used Crown Use defence.

Acting for Eli Lilly in its dispute with Actavis over Lilly's Alimta cancer treatment in relation to dextrose remission issues.

Acting for HTC in litigation (i) against Philips in relation to alleged SEPs, and (ii) against Nokia in relation to a large number of both alleged SEPs and non essential patents.

Acting for Merck and Du Pont on first UK cases challenging European legislation regarding pediatric extensions to supplementary protection certificates; won extension for Du Pont.

Acting in arbitration proceedings for a major WCDMA infrastructure manufacturer relating to a dispute over licence fees for telecoms SEPs and the applicability of FRAND licence terms.

Advising NYSE-listed AmerisourceBergen Corporation on IP aspects of its US$6.47 billion acquisition of Walgreens Boots Alliance, Inc.’s Alliance Healthcare wholesale distribution business in Europe.

Acting for ZTE in its multi patent cross border litigation with Ericsson in relation to patents said to be essential to 2G/3G telecoms standards.

Advising Novartis on IP aspects of its strategic artificial intelligence and data science collaboration with Microsoft as it founded the Novartis AI Innovation Lab.

Acting for a leading manufacturer of innovative smartphones on a number of cross border patent licensing disputes against Ericsson and Nokia with respect to SEPs and NEP phone & computer patents.

Acting for Novartis on IP aspects of its acquisition of GSK's oncology products for an aggregate cash consideration of US$16bn.

Acting in arbitration proceedings for a major communications device manufacturer in relation to a number of potential SEPs and related licence terms.

Advising one of world's leading food and beverage companies on IP aspects of business separation; various joint development arrangements; drafting and negotiating related contractual provisions.

Acting for Qualcomm in its patent action against Nokia in relation to GPRS and EDGE mobile phone technology, and co-ordinating related patent actions across jurisdictions.